Who Are the Leaders in the Emerging Biosimilar Drugs Market? Visiongain’s New Analysis Gives Company Assessments, Discussions and Predictions
Where are companies in the Biosimilar market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 233-page report provides 126 tables, charts, and graphs, giving a clear view on companies in the biosimilar market. Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover this information in our updated report, which analyses 25 leading developers, producers and marketers of biosimilars. The report also covers other firms, including big pharma companies entering that industry.
Molecules giving rise to biosimilars – explore where progress occurs
Our report discusses biosimilar competition for these five therapeutic agents – products and research and development:
• Adalimumab
• Infliximab
• Etanercept
• Darbepoetin alpha
• Rituximab.
In particular, our report analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel:
• Hospira (Pfizer)
• Mylan
• Sandoz (Novartis)
• STADA Arzneimittel
• Teva Pharmaceutical Industries
Chapter 5 profiles leading companies in China:
• 3SBio
• Beijing ShuangLu Pharmaceutical Co.
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceutical Group
• Tonghua Dongbao Pharmaceutical Co.
Chapter 6 profiles leading companies in India:
• Biocon
• Dr. Reddy’s Laboratories
• Intas Biopharmaceuticals
• Ranbaxy (Sun Pharma)
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila
Chapter 7 profiles leading companies in Latin America:
• Amega Biotech
• Biosidus
• Probiomed
Chapter 8 profiles leading companies in the rest of the world:
• Biocad
• Bioton
• Celltrion
• Dong-A
• LG Life Sciences
Our report also reviews 25 other companies rising in importance. See what is possible from 2017, discovering what leading companies do and their commercial outlooks.
With our report, you will see who and what shapes the biosimilars industry, including policies, regulatory concerns and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.
How the 25 Top Biosimilar Drug Manufacturers report helps you
In summary, our 233-page report provides you with the following knowledge:
• Profiles of 25 leading biosimilar companies and other relevant firms – assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers’ biosimilar drug sales
• R&D for biosimilars – see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials
• Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Visiongain’s study is for everybody needing commercial analyses for the leading companies in the Biosimilar market. You will find data, trends and predictions.
Get our report today Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers, 2017-2027, and Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor Biologics. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the Top Biosimilar Drug Manufacturers
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Biosimilar Drugs: World Market Forecast, 2017-2027
2.1 Introduction to Biologics and Biosimilars
2.1.1 Biologic Drugs Definition and Overview
2.1.2 Biosimilars Drugs Definition and Overview
2.1.3 How do Biosimilars Differ from Generics?
2.2 The World Biosimilar Market, 2017-2027
2.3 Overall World Biosimilars Revenue Forecast, 2017-2027
2.4 Biosimilars – Realising their Potential, Market Drivers
2.4.1 Biosimilar Approval Pathways and Regulations
2.4.2 India Releases New Biosimilar Development Guidelines
2.4.3 Russia: Lack of Regulatory Framework Works Well in the Short Term
2.4.4 ‘Pharma 2020’ Initiative
2.4.5 South Korean Market has benefitted from Early Biosimilar Guidelines
2.4.6 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2016
2.4.7 Brazil: ANVISA’s Biosimilar Regulations Are Similar the EMA’s
2.4.8 The Outlook for Biosimilar mAbs in the EU
2.4.9 The Outlook for Biosimilar mAbs in Japan
2.4.10 Emerging Markets for Biosimilars
2.4.11 Start-up Pressure on Market Leaders
2.4.12 The Patent Cliff for Biologics
2.5 Biosimilars: Market Restraints
2.5.1 Market Fragmentation for Biosimilar Products
2.5.2 Innovative Biologics – Rendering Biosimilars Useless?
2.5.3 Biobetters – A Growing Threat
2.5.4 BREXIT and Trump Election – A Rising Political Threat
3. Leading Biologic & Biosimilar Products: Overview, 2017
3.1 Humira: Product Overview
3.1.1 Adalimumab Biosimilars – Zydus Cadila
3.1.2 Adalimumab Biosimilars – Amgen-Actavis
3.1.3 Adalimumab Biosimilars – Sandoz
3.1.4 Adalimumab Biosimilars – Momenta Pharmaceuticals
3.1.5 Adalimumab Biosimilars – Pfizer
3.1.6 Adalimumab Biosimilars – Boehringer Ingelheim
3.2 Remicade: Product Overview
3.2.1 Infliximab Biosimilar – Epirus Pharmaceuticals & Ranbaxy
3.2.2 Infliximab Biosimilar – Celltrion & Hospira & Alvogen
3.3 Enbrel: Product Overview
3.3.1 Etanercept Biosimilar – Cipla & Shanghai CP Guojian
3.3.2 Etanercept Biosimilar – Daiichi Sankyo & Coherus Biosciences
3.4 Aranesp: Product Overview
3.4.1 Darbepoetin Alpha Biosimilar – Dr. Reddy’s Laboratories
3.4.2 Darbepoetin Alpha Biosimilar – Cipla & Hetero Drugs Limited
3.4.3 Darbepoetin Alpha Biosimilar – Hospira
3.5 Rituxan: Product Overview
3.5.1 Rituximab Biosimilar – Sandoz
3.5.2 Rituximab Biosimilar – Amgen
3.5.3 Rituximab Biosimilar – Boehringer Ingelheim
3.5.4 Rituximab Biosimilar – Dr. Reddy’s Laboratories
3.5.5 Rituximab Biosimilar – Pfizer
3.5.6 Rituximab Biosimilar – Difficulties Seen in Trials
4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2017
4.1 Sandoz – Company Overview & Analysis
4.1.1 Sandoz Biosimilar Products
4.1.2 Sandoz Biosimilars Market Forecast, 2017-2027
4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook
4.2 Teva Pharmaceuticals – Company Overview & Analysis
4.2.1 Teva Biosimilar Products
4.2.2 Teva Biosimilar Market Forecast, 2017-2027
4.2.3 Teva Biosimilar Pipeline & Future Outlook
4.3 Hospira (Pfizer) – Company Overview & Analysis
4.3.1 Hospira Biosimilar Products
4.3.2 Hospira Biosimilars Pipeline & Future Strategies
4.4 STADA Arzneimittel – Company Overview & Analysis
4.4.1 STADA Biosimilar Products
4.4.2 STADA Biosimilars Pipeline & Future Outlook
4.5 Mylan – Company Biosimilar & Analysis
4.5.1 Mylan Biosimilar Products
4.5.2 Mylan Biosimilar Market Forecast, 2017-2027
4.5.3 Mylan Biosimilars Pipeline & Future Outlook
4.6 Other Biosimilars Companies in the US
4.6.1 Impax Laboratories Inc. – Company Overview & Analysis
4.6.2 Bristol-Myers Squibb – Company Overview & Analysis
4.6.3 Merck & Co. – Company Overview & Analysis
4.6.4 Eli Lilly - Company Overview & Analysis
4.7 Other Biosimilar Companies in Europe
4.7.1 BioXpress Therapeutics – Company Overview & Analysis
4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis
4.7.3 Finox Biotech – Company Overview & Analysis
5. Leading Biosimilar Manufacturers in China, 2016
5.1 S3Bio – Company Overview & Analysis
5.1.1 3SBio Biosimilar Products
5.1.2 3SBio Biosimilars Market Forecast, 2017-2027
5.1.3 3SBio Biosimilars Pipeline & Future Outlook
5.2 Qilu Pharmaceutical – Company Overview & Analysis
5.2.1 Qilu Pharmaceutical Biosimilar Products
5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.3 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis
5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
5.4 Tonghua Dongbao – Company Overview & Analysis
5.4.1 Tonghua Dongbao Biosimilar Products
5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
5.5 Beijing ShuangLu Pharmaceuticals – Company Overview & Analysis
5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products
5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.6 Other Biosimilars Companies in China
5.6.1 Shanghai CP Guojian – Company Overview & Analysis
5.6.2 Zhejiang Hisun – Company Overview & Analysis
5.6.3 Innovent Biologics – Company Overview & Analysis
5.6.4 Shanghai Celgen Biopharmaceutical – Company Overview & Analysis
6. Leading Biosimilar Manufacturers in India, 2016
6.1 Biocon – Company Overview & Analysis
6.1.1 Biocon Biosimilar Products
6.1.2 Biocon Biosimilars Market Forecast, 2017-2027
6.1.3 Biocon Biosimilars Pipeline & Future Outlook
6.2 Dr. Reddy’s Laboratories – Company Overview & Analysis
6.2.1 Dr. Reddy’s Laboratories Biosimilar Products
6.2.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Outlook
6.3 Wockhardt – Company Overview & Analysis
6.3.1 Wockhardt Biosimilar Products
6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook
6.4 Zydus Cadila – Company Overview & Analysis
6.4.1 Zydus Cadila Biosimilar Products
6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook
6.5 Ranbaxy (Sun Pharma) – Company Overview & Analysis
6.5.1 Ranbaxy Biosimilar Products
6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook
6.6 Reliance Life Sciences – Company Overview & Analysis
6.6.1 Reliance Life Sciences Biosimilar Products
6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook
6.7 Intas Biopharmaceuticals – Company Overview & Analysis
6.7.1 Intas Biopharmaceuticals Biosimilar Products
6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
6.8 Other Indian Biosimilars Companies
6.8.1 Emcure Pharmaceuticals – Company Overview & Analysis
6.8.2 Shreya Life Sciences – Company Overview & Analysis
6.8.3 Cipla – Company Overview & Analysis
6.8.4 Shantha Biotechnics – Company Overview & Analysis
7. Leading Biosimilar Manufacturers in Latin America, 2016
7.1 Probiomed – Company Overview & Analysis
7.1.1 Probiomed Biosimilar Products
7.1.2 Probiomed Biosimilars Pipeline & Future Strategies
7.2 Biosidus – Company Overview & Analysis
7.2.1 Biosidus Biosimilar Products
7.2.2 Biosidus Biosimilars Pipeline & Future Strategies
7.3 Amega Biotech – Company Overview and Analysis
7.3.1 Amega – Biosimilar Products
7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies
7.4 Other Biosimilars Companies in South America
7.4.1 Bionovis – Company Overview & Analysis
7.4.2 Orygen Biotecnologia – Company Overview & Analysis
7.4.3 Recepta – Company Overview & Analysis
8. Leading Biosimilar Manufacturers in the Rest of the World, 2016
8.1 Celltrion – Company Overview & Analysis
8.1.1 Celltrion Biosimilar Products
8.1.2 Celltrion Biosimilars Pipeline & Future Strategies
8.2 LG Life Sciences – Company Overview & Analysis
8.2.1 LG Life Sciences Biosimilar Products
8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies
8.3 Dong-A – Company Overview & Analysis
8.3.1 Dong-A Biosimilar Products
8.3.2 Dong-A Biosimilars Pipeline & Future Strategies
8.4 Bioton – Company Overview & Analysis
8.4.1 Bioton’s Biosimilar Products
8.4.2 Bioton’s Biosimilars Pipeline & Future Strategies
8.5 Biocad – Company Overview & Analysis
8.5.1 Biocad’s Biosimilar Products
8.5.2 Biocad’s Biosimilars Pipeline & Future Strategies
8.6 Other Biosimilars Companies in the RoW
8.6.1 Gedeon-Richter – Company Overview & Analysis
8.6.2 Egis Pharmaceuticals - Company Overview & Analysis
8.6.3 JCR Pharmaceuticals – Company Overview & Analysis
8.6.4 Nippon Kayaku – Company Overview & Analysis
8.6.5 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis
8.6.6 Daiichi Sankyo – Company Overview & Analysis
9. Qualitative Analysis of Biosimilars Market: 2017-2027
9.1 SWOT Analysis of the Global Biosimilars Industry and Market: 2017-2027
9.1.1 Strengths
9.1.2 Weaknesses
9.1.3 Opportunities
9.1.4 Threats
9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2017 -2027
9.2.1 Social Factors
9.2.2 Technological Factors
9.2.3 Economic Factors
9.2.4 Political Factors
10. Conclusions
10.1 Market Leaders Among Biosimilar Manufacturers
10.2 Will Sandoz Retain its Position as Market Leader?
10.3 Which Companies Are Best Placed to Lead in Future?
10.4 Big Pharma Companies Will Try Gain Market Entry
10.5 Contribution of Chinese and Indian Companies will Grow
10.6 Strong R&D Pipeline – Driver for Growth
10.7 Concluding Remarks
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Biosimilars Market Segmentation, 2016
Figure 2.1 Global Biosimilar Market: Revenue Forecast ($bn), 2017-2027
Figure 2.2 Global Biosimilar Market Drivers, 2017
Figure 2.3 Global Biosimilar Market Restraints, 2017
Figure 4.1 Sandoz: Biosimilar Products Revenue Forecast ($bn), 2017-2027
Figure 4.2 Teva Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
Figure 4.3 Mylan Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
Figure 5.1 S3Bio Pharmaceuticals: Biosimilar Products Revenue Forecast ($bn), 2017-2027
Figure 6.1 Biocon: Biosimilar Products Revenue Forecast ($bn), 2017-2027
Figure 9.1 SWOT Analysis of the Biosimilars Market, 2017
Figure 9.2 STEP Analysis of the Biosimilars Market, 2017
List of Tables
Table 2.1 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2016-2021
Table 2.2 Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2021-2027
Table 2.3 Finalised US FDA Biosimilar Guidelines
Table 3.1 Humira Biologic Analysis, 2017
Table 3.2 Remicade Biologic Analysis, 2017
Table 3.3 Enbrel Biologic Analysis, 2017
Table 3.4 Aranesp: Biologic Analysis, 2017
Table 3.5 Rituxan: Biologic Analysis, 2017
Table 4.1 Sandoz: Company Overview, 2017
Table 4.2 Sandoz: Biosimilars Product Portfolio, 2017
Table 4.3 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 4.4 Sandoz: Biosimilar Products Forecast: Revenue ($bn), AGR (%),
Table 4.5 Sandoz: Biosimilar Developments Overview, 2017
Table 4.6 Teva: Company Overview, 2017
Table 4.7 Teva: Biosimilars Overview, 2017
Table 4.8 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 4.9 Teva Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 4.10 Hospira: Company Overview, 2017
Table 4.11 Hospira: Company Overview, 2017
Table 4.12 Hospira: Biosimilar Developments Overview, 2017
Table 4.13 Stada Arzneimittel: Company Overview, 2017
Table 4.14 Stada Arzneimittel: Biosimilars Overview, 2017
Table 4.15 Stada Arzneimittel: Biosimilar Developments Overview, 2017
Table 4.16 Mylan: Company Overview, 2017
Table 4.17 Mylan: Biosimilars Overview, 2017
Table 4.18 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 4.19 Mylan Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 4.20 Mylan: Biosimilar Developments Overview, 2017
Table 4.21 Impax Laboratories: Company Overview, 2017
Table 4.22 Bristol-MyersSquibb: Company Overview, 2017
Table 4.23 Merck & Co.: Company Overview, 2017
Table 4.24 Merck & Co.: Biosimilars Product Pipeline, 2017
Table 4.25 Eli Lilly: Company Overview, 2017
Table 4.26 Eli Lilly: Biosimilars Product Portfolio, 2017
Table 4.27 BioXpress Therapeutics: Company Overview, 2017
Table 4.28 Medice Arzneimittel Pütter: Company Overview, 2017
Table 4.29 Finox Biotech: Company Overview, 2017
Table 5.1 3SBio: Company Overview, 2017
Table 5.2 3SBio: Biosimilars Overview, 2017
Table 5.3 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 5.4 3SBio Pharmaceuticals: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 5.5 3SBio: Biosimilar Developments Overview, 2017
Table 5.6 Qilu Pharmaceutical: Company Overview, 2017
Table 5.7 Qilu Pharmaceutical: Biosimilars Overview, 2017
Table 5.8 Qilu Pharmaceutical: Biosimilar Developments Overview, 2017
Table 5.9 Shanghai Fosun: Company Overview, 2017
Table 5.10 Shanghai Fosun: Biosimilars Overview, 2017
Table 5.11 Shanghai Fosun: Biosimilar Developments Overview, 2017
Table 5.12 Tonghua Dongbao: Company Overview, 2017
Table 5.13 Tonghua Dongbao: Biosimilars Overview, 2017
Table 5.14 Tonghua Dongbao: Biosimilar Developments Overview, 2017
Table 5.15 Beijing ShuangLu: Company Overview, 2017
Table 5.16 Beijing ShuangLu: Biosimilars Overview, 2017
Table 5.17 Beijing ShuangLu: Biosimilar Developments Overview, 2017
Table 5.18 Shanghai CP Guojian: Company Overview, 2017
Table 5.19 Zhejiang Hisun: Company Overview, 2017
Table 5.20 Innovent Biologics: Biosimilars Overview, 2017
Table 5.21 Shanghai Celgen Biopharmaceutical: Company Overview, 2017
Table 6.1 Biocon: Company Overview, 2017
Table 6.2 Biocon: Biosimilars Product Portfolio, 2017
Table 6.3 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
Table 6.4 Biocon: Biosimilar Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
Table 6.5 Biocon: Biosimilars Pipeline, 2017
Table 6.6 Dr. Reddy’s Laboratories: Company Overview, 2017
Table 6.7 Dr. Reddy’s Laboratories: Biosimilar Products, 2017
Table 6.8 Dr. Reddy’s Laboratories: Biosimilars Pipeline, 2017
Table 6.9 Wockhardt: Company Overview, 2017
Table 6.10 Wockhardt: Biosimilar Products, 2017
Table 6.11 Wockhardt: Biosimilars Pipeline, 2017
Table 6.12 Zydus Cadila: Company Overview, 2017
Table 6.13 Zydus Cadila: Biosimilars Product Portfolio, 2017
Table 6.14 Zydus Cadila: Biosimilars Pipeline, 2017
Table 6.15 Ranbaxy: Company Overview, 2017
Table 6.16 Ranbaxy: Biosimilars Product Portfolio, 2017
Table 6.17 Zenotech: Biosimilars Pipeline, 2017
Table 6.18 Reliance Life Sciences: Company Overview, 2017
Table 6.19 Reliance Life Sciences: Biosimilar Products, 2017
Table 6.20 Reliance Life Sciences: Biosimilars Pipeline, 2017
Table 6.21 Intas Biopharmaceuticals: Company Overview, 2017
Table 6.22 Intas Biopharmaceuticals: Biosimilar Products Portfolio, 2017
Table 6.23 Intas Biopharmaceuticals: Biosimilars Pipeline, 2017
Table 6.24 Emcure Pharmaceuticals: Company Overview, 2017
Table 6.25 Shreya Life Sciences: Company Overview, 2017
Table 6.26 Cipla: Company Overview, 2017
Table 6.27 Shantha Biotechnics: Company Overview, 2017
Table 7.1 Probiomed: Company Overview, 2017
Table 7.2 Probiomed Biosimilars Product Portfolio, 2017
Table 7.3 Biosidus: Company Overview, 2017
Table 7.4 Biosidus: Biosimilars Product Portfolio, 2017
Table 7.5 Biosidus: Biosimilars Pipeline, 2017
Table 7.6 Amega Biotech: Company Overview, 2017
Table 7.7 Amega Biotech: Biosimilars Product Portfolio , 2017
Table 7.8 Bionovis: Company Overview, 2017
Table 7.9 Orygen Biotechnologia: Company Overview, 2017
Table 7.10 Recepta: Company Overview, 2017
Table 8.1 Celltrion: Company Overview, 2017
Table 8.2 Celltrion: Biosimilars Overview, 2017
Table 8.3 Celltrion: Biosimilars Product Pipeline, 2017
Table 8.4 LG Life Sciences: Company Overview, 2017
Table 8.5 LG Life Sciences: Biosimilars Product Portfolio, 2017
Table 8.6 LG Life Sciences: Biosimilars Pipeline, 2017
Table 8.7 Dong-A: Company Overview, 2017
Table 8.8 Dong-A: Biosimilar Product Portfolio, 2017
Table 8.9 Dong-A: Biosimilar Pipeline, 2017
Table 8.10 Bioton: Company Overview, 2017
Table 8.11 Bioton: Biosimilars Product Portfolio, 2017
Table 8.12 Biocad: Company Overview, 2017
Table 8.13 Biocad: Biosimilars Product Portfolio, 2017
Table 8.14 Biocad: Biosimilars Pipeline, 2017
Table 8.15 Gedeon-Richter: Company Overview, 2017
Table 8.16 Egis Pharmaceuticals: Company Overview, 2017
Table 8.17 JCR Pharmaceuticals: Company Overview, 2017
Table 8.18 Nippon Kayaku: Company Overview, 2017
Table 8.19 Fujifilm Kyowa Kirin Biologics: Company Overview, 2017
Table 8.20 Daiichi Sankyo: Company Overview, 2017
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
